Peptides Weight LossMetabolic Human RCT evidence

Dulaglutide (Trulicity)

Trulicity · Dula

5 days

Half-life

0.75–4.5 mg

Typical dose

Chronic (ongoing)

Cycle length

Long-acting GLP-1 agonist for type 2 diabetes and weight loss; weekly subcutaneous injection.

Key takeaways

Once-weekly GLP-1 agonist approved for type 2 diabetes and cardiovascular risk reduction in T2D.
Not approved for obesity, though commonly used off-label for weight loss.
Roughly 5-day half-life; label titrates 0.75 mg weekly up to 4.5 mg.
REWIND trial showed reduced cardiovascular events in T2D patients.

Overview

What it is

Dulaglutide (Trulicity) is a long-acting GLP-1 receptor agonist approved for type 2 diabetes, with an added indication for reducing cardiovascular risk in adults with T2D. Despite widespread off-label use for weight loss, it isn't approved for obesity. It mimics GLP-1: glucose-dependent insulin release, glucagon suppression, slower gastric emptying, and reduced appetite.

Pharmacokinetics

The roughly 5-day half-life supports once-weekly subcutaneous injection. A modified Fc-fusion structure resists DPP-4 degradation and slows renal clearance. Label titration runs from 0.75 mg up to 4.5 mg weekly to manage dose-dependent GI side effects.

What the evidence says

Dulaglutide is FDA-approved with extensive RCT evidence, including the REWIND cardiovascular outcomes trial, which showed reduced major adverse cardiovascular events in T2D. The main risks are class-typical: nausea and GI effects, plus label warnings for pancreatitis and thyroid C-cell tumors seen in rodents.

Reported dosing protocols

Protocols reported in research literature and clinic/community use — informational context, not a dosing recommendation.

Use case	Dose	Route	Frequency	Duration
Type 2 diabetes (label)	0.75 mg start, escalate to 1.5 mg; up to 3 or 4.5 mg	SubQ	Once weekly	Chronic

Pharmacokinetic summary

Model tier: Simple (t½ + F, Tmax estimated)
Half-life: 5 days
Bioavailability: 80%
Typical dose: 0.75–4.5 mg

Frequently asked questions

Is dulaglutide approved for weight loss?

No. Trulicity is approved for type 2 diabetes and for reducing cardiovascular risk in T2D, not for chronic weight management. Weight loss occurs, but it's modest compared with drugs approved for obesity such as tirzepatide or semaglutide 2.4 mg.

How long does dulaglutide take to reach steady state?

With a roughly 5-day half-life, steady state takes about 2–4 weeks of weekly dosing. That's why the label spaces dose increases at least 4 weeks apart.

What are the main side effects of dulaglutide?

Nausea, vomiting, and diarrhea are the most common and are dose-dependent. The label warns about pancreatitis and thyroid C-cell tumors seen in rodents; it's contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2.

References

FDA Trulicity label (2020) — Elimination half-life ~5 days (range 3.9-6.1 days). Once-weekly SC dosing.
FDA Trulicity prescribing information — Approved indications, roughly 5-day half-life, and the weekly titration schedule.
REWIND trial, Lancet 2019 — Cardiovascular outcomes RCT: dulaglutide reduced major adverse cardiovascular events in T2D.

Comments

Loading comments…